QRG Capital Management Inc. Boosts Stock Holdings in Takeda Pharmaceutical Co. $TAK

QRG Capital Management Inc. boosted its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 11.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 432,654 shares of the company’s stock after buying an additional 45,726 shares during the period. QRG Capital Management Inc.’s holdings in Takeda Pharmaceutical were worth $6,689,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in Takeda Pharmaceutical during the 1st quarter worth approximately $37,000. Farther Finance Advisors LLC increased its stake in Takeda Pharmaceutical by 29.2% during the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after buying an additional 1,045 shares in the last quarter. Fifth Third Bancorp increased its stake in Takeda Pharmaceutical by 85.5% during the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company’s stock worth $78,000 after buying an additional 2,411 shares in the last quarter. GAMMA Investing LLC increased its stake in Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock worth $105,000 after buying an additional 1,296 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Takeda Pharmaceutical during the 1st quarter worth approximately $125,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have commented on TAK. Zacks Research lowered Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 21st. Weiss Ratings restated a “hold (c)” rating on shares of Takeda Pharmaceutical in a report on Saturday, September 27th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold”.

Takeda Pharmaceutical Trading Up 1.2%

Shares of Takeda Pharmaceutical stock opened at $14.62 on Monday. The stock has a market cap of $46.50 billion, a P/E ratio of 48.72 and a beta of 0.21. The stock’s 50 day simple moving average is $14.84 and its 200-day simple moving average is $14.82. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $15.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The firm had revenue of $7.45 billion for the quarter, compared to analysts’ expectations of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.